Reviewing Rapid Micro Biosystems (NASDAQ:RPID) and Bullfrog AI (NASDAQ:BFRG)

Bullfrog AI (NASDAQ:BFRG) and Rapid Micro Biosystems (NASDAQ:RPID) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Profitability

This table compares Bullfrog AI and Rapid Micro Biosystems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-150.36%	-127.98%
Rapid Micro Biosystems	-145.56%	-177.04%	-73.12%

Analyst Recommendations

This is a summary of current recommendations and price targets for Bullfrog AI and Rapid Micro Biosystems, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1	1	0	0	1.50
Rapid Micro Biosystems	1	0	2	0	2.33

Rapid Micro Biosystems has a consensus price target of $6.00, suggesting a potential upside of 440.54%. Given Rapid Micro Biosystems’ stronger consensus rating and higher possible upside, analysts clearly believe Rapid Micro Biosystems is more favorable than Bullfrog AI.

Valuation and Earnings

This table compares Bullfrog AI and Rapid Micro Biosystems”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$120,000.00	102.84	-$6.50 million	($0.46)	-1.45
Rapid Micro Biosystems	$33.59 million	1.66	-$47.12 million	($1.12)	-0.99

Bullfrog AI has higher earnings, but lower revenue than Rapid Micro Biosystems. Bullfrog AI is trading at a lower price-to-earnings ratio than Rapid Micro Biosystems, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 52.6% of Rapid Micro Biosystems shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by company insiders. Comparatively, 12.7% of Rapid Micro Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Bullfrog AI has a beta of -2.71, meaning that its stock price is 371% less volatile than the S&P 500. Comparatively, Rapid Micro Biosystems has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.

Summary

Rapid Micro Biosystems beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.